Adamska A, Falasca M. ATP-binding cassette transporters in progression and clinical outcome of pancreatic cancer: What is the way forward? World J Gastroenterol 2018; 24(29): 3222-3238 [PMID: 30090003 DOI: 10.3748/wjg.v24.i29.3222]
Corresponding Author of This Article
Marco Falasca, PhD, Professor, Metabolic Signalling Group, School of Pharmacy and Biomedical Sciences, Curtin Health Innovation Research Institute, Curtin University, GPO Box U1987, Perth 6102, WA, Australia. marco.falasca@curtin.edu.au
Research Domain of This Article
Oncology
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Aug 7, 2018; 24(29): 3222-3238 Published online Aug 7, 2018. doi: 10.3748/wjg.v24.i29.3222
ATP-binding cassette transporters in progression and clinical outcome of pancreatic cancer: What is the way forward?
Aleksandra Adamska, Marco Falasca
Aleksandra Adamska, Marco Falasca, Metabolic Signalling Group, School of Pharmacy and Biomedical Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth 6102, WA, Australia
Author contributions: Both authors equally contributed to the conception and realization of the review.
Supported byAvner Pancreatic Cancer Foundation.
Conflict-of-interest statement: No potential conflicts of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Marco Falasca, PhD, Professor, Metabolic Signalling Group, School of Pharmacy and Biomedical Sciences, Curtin Health Innovation Research Institute, Curtin University, GPO Box U1987, Perth 6102, WA, Australia. marco.falasca@curtin.edu.au
Telephone: +61-8-92669712
Received: May 2, 2018 Peer-review started: May 4, 2018 First decision: May 17, 2018 Revised: May 31, 2018 Accepted: June 27, 2018 Article in press: June 27, 2018 Published online: August 7, 2018
Core Tip
Core tip: Pancreatic cancer is one of the deadliest cancers due to its highly aggressive biology and resistance to broad range of therapeutics. Expression of ATP-binding cassette (ABC) transporters by cancer cells is one of the main mechanisms responsible for the lowered drug accumulation. However, the attempts made in multidrug resistance reversal by the inhibition of their activity have not provided satisfactory results in clinical trials. Nevertheless, current knowledge on the role played by ABC transporters in carcinogenesis beyond chemoresistance, could create the opportunity for the development of novel, direct targeted therapeutic strategies. Additionally, the association between ABC transporters expression and pancreatic ductal adenocarcinoma patients’ prognosis and response to applied therapies confirms their pharmacological potential.
